Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

953
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
953
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.1K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.1K
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

2.2K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.2K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

1.6K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.6K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

1.4K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Promoting best practice in assessment - a professional development initiative for optometry programs.

Clinical & experimental optometry·2025
Same author

Could entrustable professional activities support assessment in optometric clinical education in Australia and New Zealand?

Clinical & experimental optometry·2025
Same author

Antimicrobial stewardship and education in optometry.

Clinical & experimental optometry·2024
Same author

Ocular Biometry Percentile Curves and Their Relation to Myopia Development in Indian Children.

Journal of clinical medicine·2024
Same author

Prevalence of myopia among urban and suburban school children in Tamil Nadu, South India: findings from the Sankara Nethralaya Tamil Nadu Essilor Myopia (STEM) Study.

Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)·2022
Same author

The Sankara Nethralaya Tamil Nadu Essilor Myopia (STEM) Study-Defining a Threshold for Non-Cycloplegic Myopia Prevalence in Children.

Journal of clinical medicine·2021

Related Experiment Video

Updated: Jan 13, 2026

Inducement and Evaluation of a Murine Model of Experimental Myopia
07:20

Inducement and Evaluation of a Murine Model of Experimental Myopia

Published on: January 22, 2019

10.4K

Translational changes: evidence for low-dose atropine and myopia control.

Simon Backhouse1, Linda Robinson1, Christopher Law1

  • 1School of Medicine, Deakin University, Geelong, Australia.

Clinical & Experimental Optometry
|January 6, 2026
PubMed
Summary

Low-dose atropine eye drops are a key option for myopia control in children, offering an alternative to high-dose treatments with fewer side effects. This review explores the benefits and drawbacks of low-dose atropine for practitioners.

Keywords:
Atropinelow-dosemyopiamyopia controlrefractive error

More Related Videos

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
05:56

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model

Published on: April 3, 2016

9.3K
Author Spotlight: Exploring Press Needle Efficacy and Underlying Molecular Pathways
05:26

Author Spotlight: Exploring Press Needle Efficacy and Underlying Molecular Pathways

Published on: April 12, 2024

2.5K

Related Experiment Videos

Last Updated: Jan 13, 2026

Inducement and Evaluation of a Murine Model of Experimental Myopia
07:20

Inducement and Evaluation of a Murine Model of Experimental Myopia

Published on: January 22, 2019

10.4K
Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
05:56

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model

Published on: April 3, 2016

9.3K
Author Spotlight: Exploring Press Needle Efficacy and Underlying Molecular Pathways
05:26

Author Spotlight: Exploring Press Needle Efficacy and Underlying Molecular Pathways

Published on: April 12, 2024

2.5K

Area of Science:

  • Ophthalmology
  • Optometry
  • Pediatric Eye Care

Background:

  • Myopia prevalence is rising globally, increasing risks of associated pathologies.
  • Myopia control, focusing on preventing axial elongation, is now the standard of care for pediatric myopia.
  • Pharmacological interventions, like atropine, are crucial for myopia management.

Purpose of the Study:

  • To review the efficacy and safety of low-dose atropine (<0.1%) for pediatric myopia control.
  • To provide an evidence-based approach for practitioners considering low-dose atropine.
  • To compare low-dose atropine with higher concentrations regarding visual side effects.

Main Methods:

  • Literature review of studies on atropine for myopia control.
  • Analysis of publications and prescribing trends for low-dose atropine.
  • Evaluation of clinical data on efficacy and adverse events.

Main Results:

  • Low-dose atropine shows promising myopia control effects with reduced visual side effects compared to 1% atropine.
  • There has been a significant increase in research and clinical use of low-dose atropine.
  • Cycloplegia and mydriasis are significant side effects of 1% atropine, less so with low-dose formulations.

Conclusions:

  • Low-dose atropine is an effective and well-tolerated option for pediatric myopia control.
  • Practitioners should consider low-dose atropine as a viable strategy to prevent myopia progression.
  • Further evidence-based research supports the integration of low-dose atropine into clinical practice.